HEREDITARY multiple exostoses are a distinct clinical entity more frequently encountered than is generally appreciated. We have recently had the opportunity of studying 4 members of a Negro family who ...
Researchers have led a preclinical study demonstrating that the drug palovarotene suppresses the formation of bony tumors (osteochondromas) in models of multiple hereditary exostoses (MHE). The ...
Researchers have created a mouse model for multiple hereditary exostoses, a debilitating, childhood bone disease, which can only be treated with surgery. Now begins the search for new treatments.
Patients with multiple hereditary exostoses (MHE)—a rare disease that causes the growth of multiple benign bone tumors—have limited treatment options. The genetic disorder affects roughly 1 in 50,000 ...
This publication was sponsored by Ipsen Pharma. Fibrodysplasia ossificans progressiva (FOP) and multiple osteochondromas (MO) are 2 rare and debilitating bone disorders that can have a serious impact ...
Sign up for our Brooklyn Paper email newsletter to get news, updates, and local insights delivered straight to your inbox! On Sunday, September 13, at The El Caribe ...
Children born with multiple hereditary exostoses (MHE) suffer from abnormal growths on their bones. These bony protrusions stunt their growth and can cause pain and disfigurement. Scientists have long ...
La Jolla, Calif., November 20, 2017 - Researchers at Sanford Burnham Prebys Medical Discovery Institute (SBP) have led a preclinical study demonstrating that the drug palovarotene suppresses the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback